Dynavax Pharma (DVAX): Net earnings per share for the last 12 months

Symbol and logo of brand Dynavax Technologies (DVAX)

Dynavax Technologies (DVAX) leads in the development of advanced vaccines and CpG 1018 platforms, investing in the fight against liver infections. Fundamental net income per share TTM demonstrates yield dynamics, with the indicator fixed at -0.38. An impeccable brand image is confirmed by physician trust in hepatitis B medications. A stable cash flow is ensured by strong demand for the flagship product.

DVAX (Dynavax) Net earnings per one share for the last twelve months history from 07/04/2022 to 02/21/2026

Financial and market metric breakdowns for dynavax.com (DVAX)

- stock price and consensus target price:
- stock exchange capitalization data:
Basic company analysis:DVAX - Dynavax Corp
Manufactured products of Dynavax Technologies

The indicator calculates the ratio of net income to the total number of shares over a rolling year, measuring the actual efficiency of capital generation per share. Steady growth in the rolling earnings per share history confirms the transition of Dynavax Technologies (DVAX) from startup status to that of a reliable player, converting high confidence in hepatitis B vaccines into a sustainable financial result.